Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-α
✍ Scribed by Yoshida, Jun; Takaoka, Toru; Mizuno, Masaaki; Momota, Hiroshi; Okada, Hidechika
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 499 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
With the aim of developing an effective immunotherapy for malignant glioma, glioma cells were incubated with tumor necrosis factor-a (TNF-a) to increase their susceptibility to lysis by lymphokine-activated killer (LAK) cells. Treatment with exogenous TNF-a induced the expression of intercellular adhesion molecule-I (ICAM-1) on the surface of glioma cells. In addition, the cytolytic activity of LAK cells toward exogenous TNF-a-treated glioma cells was significantly greater than LAK cell activity toward untreated glioma cells. This increase in cytolytic activity was blocked by anti-ICAM-1 monoclonal antibodies (MAb). Furthermore, co-treatment with a bifunctional antibody (BFA) composed of anti-CD3 (UCHTl ) and antiglioma (G-22) antibodies synergistically increased the cytolytic activity of LAK cells towards TNF-a-treated glioma cells. These results indicate that a combination of exogenous TNF-a and anti-CD3/ antiglioma BFA may provide an effective modified adoptive immunotherapy for patients with malignant glioma.